Evaluation of the association between Anti-alpha V beta 6 integrin antibody and the clinical course of ulcerative colitis after the induction therapy of Bio-JAK

Evaluation of the association between Anti-alpha V beta 6 integrin antibody and the clinical course of ulcerative colitis after the induction therapy of Bio-JAK - Evaluation of the association between Anti-alpha V beta 6 integrin antibody and the clinical course of ulcerative colitis after the induction therapy of Bio-JAK

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053098

Enrollment

100

Registered

2023-12-14

Start date

2017-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Patients enrolled in the "Comprehensive analysis in patients with ulcerative colitis and Crohn's disease using biologic agents" or in the "Usefulness of LRG in assessing disease activity in inflammatory bowel disease: an international multicenter clinical study". 2 Patients aged 18 years or older, regardless of gender 3 Patients with a confirmed diagnosis of UC based on the diagnostic criteria of the Research Group on Refractory Inflammatory Bowel Disease 4 Patients who used infliximab, adalimumab, golimumab, ustekinumab, vedolizumab, tofacitinib, filgotinib, upadacitinib, or miliquizumab (Bio-JAK) (regardless of previous use of biological agents).

Exclusion criteria

Exclusion criteria: 1 Pregnant women, lactating women, or patients who may be pregnant 2 Patients after total colorectal resection 3 Patients with deficient serum (0W) serum at the start of treatment 4 Patients deemed inappropriate for this study by the principal investigator (in charge) 5 No colonoscopy data before induction therapy within 6 months 6 MES 0 or 1

Design outcomes

Primary

Measure	Time frame
Remission rate and treatment continuation rate at 6/14/48W after induction therapy	—

Countries

Japan

Contacts

Public ContactShunsuke Shibui

Kitasato University Kitasato Research Institute Hospital Advanced Center for Inflammatory Bowel Disease

shibui.shunsuke@kitasato-u.ac.jp03-3444-6161

Outcome results